Key result
U73122 inhibits cardiac PLD activity via PIP2 interaction, showing it lacks PLC specificity.
U73122 inhibits myocardial PLD by interacting with PIP2, suggesting that its use as a specific PLC inhibitor may inadvertently affect PLD signaling.
U73122 lacks PLC specificity in rat myocardium; leaves open accurate dissection of phospholipase pathways in cardiac research.
The aminosteroid 1-[6-({17beta-3-methoxyestra-1,3,5(10)-trien-17-yl}amino)hexyl]-1H-pyrrole-2,5-dione (U73122) has been extensively used as a pharmacologic inhibitor of phospholipase C (PLC). The inhibitory effect of U73122 on PLC activity is most likely the result of decreased availability of phosphatidylinositol 4,5-bisphosphate (PIP2), the substrate of the PLC signal transduction pathway, rather than direct inhibition of the enzyme. PIP2 is a phospholipid with pleiotropic cellular functions, including a pivotal role in regulating cardiac phospholipase D (PLD) signal transduction. Here, we hypothesized that U73122 acts as an inhibitor of cardiac PLD activity by interference with PIP2. U73122 concentration-dependently inhibited PLD activity in rat myocardial membranes. The inhibitory effect of U73122 was significantly attenuated when assayed on solubilized PLD activity and was completely restored if solubilized PLD activity was assayed in the presence of PIP2. U73122 had no inhibitory effect on purified PLD indicating that the substance does not interact with PLD directly. These data highlight a mechanism of action of U73122 as an inhibitor of myocardial PLD by interaction with PIP2 as a cofactor for optimal PLD activity. Hence, studies using U73122 as a specific inhibitor of PLC have to take into account that PLD may be involved in some of the effects ascribed to PLC.
No takes yet. Share an insight, caveat, or question.
Burgdorf et al. (2010) studied this question. U73122 was evaluated on Phospholipase D (PLD) activity. U73122 concentration-dependently inhibited cardiac phospholipase D activity in rat myocardial membranes by interacting with PIP2, indicating it is not a specific inhibitor of PLC.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: